Cargando…
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
BACKGROUND: The bispecific monoclonal antibody emicizumab bridges activated factor IX and factor X, mimicking the cofactor function of activated factor VIII (FVIII), restoring hemostasis. OBJECTIVES: The Phase 3b STASEY study was designed to assess the safety of emicizumab prophylaxis in people with...
Autores principales: | Jiménez‐Yuste, Víctor, Peyvandi, Flora, Klamroth, Robert, Castaman, Giancarlo, Shanmukhaiah, Chandrakala, Rangarajan, Savita, García Chavez, Jaime, Martinez, Raul, Kenet, Gili, Alzahrani, Hazaa, Robson, Susan, Schmitt, Christophe, Kiialainen, Anna, Meier, Oliver, Ozelo, Margareth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663319/ https://www.ncbi.nlm.nih.gov/pubmed/36397934 http://dx.doi.org/10.1002/rth2.12837 |
Ejemplares similares
-
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023) -
Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022) -
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021) -
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022) -
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)